<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35589711</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>May</Month><Day>19</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Poly(GR) and poly(GA) in cerebrospinal fluid as potential biomarkers for C9ORF72-ALS/FTD.</ArticleTitle><Pagination><StartPage>2799</StartPage><MedlinePgn>2799</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2799</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-022-30387-4</ELocationID><Abstract><AbstractText>GGGGCC repeat expansion in C9ORF72, which can be translated in both sense and antisense directions into five dipeptide repeat (DPR) proteins, including poly(GP), poly(GR), and poly(GA), is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Here we developed sensitive assays that can detect poly(GA) and poly(GR) in the cerebrospinal fluid (CSF) of patients with C9ORF72 mutations. CSF poly(GA) and poly(GR) levels did not correlate with age at disease onset, disease duration, or rate of decline of ALS Functional Rating Scale, and the average levels of these DPR proteins were similar in symptomatic and pre-symptomatic patients with C9ORF72 mutations. However, in a patient with C9ORF72-ALS who was treated with antisense oligonucleotide (ASO) targeting the aberrant C9ORF72 transcript, CSF poly(GA) and poly(GR) levels decreased approximately 50% within 6 weeks, indicating they may serve as sensitive fluid-based biomarkers in studies directed against the production of GGGGCC repeat RNAs or DPR&#xa0;proteins.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Krishnan</LastName><ForeName>Gopinath</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA, 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raitcheva</LastName><ForeName>Denitza</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Biomarkers, Clinical Sciences Biogen, Cambridge, MA, 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartlett</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Biomarkers, Clinical Sciences Biogen, Cambridge, MA, 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prudencio</LastName><ForeName>Mercedes</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKenna-Yasek</LastName><ForeName>Diane M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA, 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Douthwright</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA, 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oskarsson</LastName><ForeName>Bj&#xf6;rn E</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ladha</LastName><ForeName>Shafeeq</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Translational Neuroscience, St. Joseph's Hospital and Medical Center and Barrow Neurological Institute, 350W Thomas Road, Phoenix, AZ, 85013, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>King</LastName><ForeName>Oliver D</ForeName><Initials>OD</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA, 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barmada</LastName><ForeName>Sami J</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0002-9604-968X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, 4005 BSRB, 109 Zina Pitcher Place, Ann Arbor, MI, 48109-2200, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Timothy M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, Saint Louis, MI, 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowser</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-5404-7259</Identifier><AffiliationInfo><Affiliation>Departments of Neurology and Translational Neuroscience, St. Joseph's Hospital and Medical Center and Barrow Neurological Institute, 350W Thomas Road, Phoenix, AZ, 85013, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watts</LastName><ForeName>Jonathan K</ForeName><Initials>JK</Initials><Identifier Source="ORCID">0000-0001-5706-1734</Identifier><AffiliationInfo><Affiliation>RNA Therapeutics Institute and Department of Biochemistry and Molecular Pharmacology, UMass Chan Medical School, Worcester, MA, 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrucelli</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials><Identifier Source="ORCID">0000-0001-6062-1528</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA, 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kankel</LastName><ForeName>Mark W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Neuromuscular &amp; Movement Disorders, Biogen, Cambridge, MA, 02142, USA. mkankel@atpresearchlabs.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Apple Tree Partners (ATP) Research Labs, Branford, CT, 06405, USA. mkankel@atpresearchlabs.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fen-Biao</ForeName><Initials>FB</Initials><Identifier Source="ORCID">0000-0001-8873-5404</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA, 01605, USA. fen-biao.gao@umassmed.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01925196</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS078398</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS111990</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS099114</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS084974</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS113943</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS101986</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS097273</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS097542</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS057553</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072931</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000622116">poly(glycyl-alanyl)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>D.R., D.B., and M.W.K. are employees and shareholders of Biogen. S.L. received research support from Biogen (Cambridge, MA), Sanofi (Paris, France), Amylyx Pharmaceuticals (Cambridge, MA), Mitsubishi Tanabe Pharma (Osaka, Japan), and consulting from Biogen (Cambridge, MA). B.O. received research support from Biogen (Cambridge, MA), Mitsubishi Tanabe Pharma America (Jersey City, NJ), MediciNova (La Jolla, CA), AZ Therapeutics (Cambridge, MA), Eisai (Tokyo, Japan), and consulting fees from Biogen (Cambridge, MA), Amylyx Pharmaceuticals, (Cambridge, MA), Mitsubishi Tanabe Pharma America (Jersey City, NJ), MediciNova (La Jolla, CA), and Tsumura (Tokyo, Japan). S.J.B. consults for Exicure (Chicago, IL), Clene (Salt Lake City, UT), KorroBio (Cambridge, MA), Faze Medicine (Cambridge, MA), and NeuroCures Foundation. T.M.M. received consulting fees from Ionis, Disarm Therapeutics, Cytokinetics and has licensing agreement with Ionis and C2N, and serves on the advisory boards of Biogen and UCB. R.B. is the founder of Iron Horse Diagnostics (Phoenix, AZ) and consults for Mitsubishi Tanabe Pharma America (Jersey City, NJ), Takeda (Tokyo, Japan), Aural Analytics (Scottsdale, AZ), and NeuroCures Foundation. J.K.W. is an ad hoc consultant for BridgeBio and Flagship Pioneering, and is on the Scientific Advisory Board of PepGen. L.P. is a consultant for Expansion therapeutics. R.H.B. consulted for Wave Life Sciences and is co-founder of Apic Bio. F.-B.G. received an honorarium from Alkermes company. The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>19</Day><Hour>23</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35589711</ArticleId><ArticleId IdType="pmc">PMC9119980</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-30387-4</ArticleId><ArticleId IdType="pii">10.1038/s41467-022-30387-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79:416&#x2013;438. doi: 10.1016/j.neuron.2013.07.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.033</ArticleId><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramzon YA, et al. The overlapping genetics of amyotrophic lateral sclerosis and frontotemporal dementia. Front. Neurosci. 2020;14:42. doi: 10.3389/fnins.2020.00042.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00042</ArticleId><ArticleId IdType="pmc">PMC7012787</ArticleId><ArticleId IdType="pubmed">32116499</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao F-B, Almeida S, Lopez-Gonzalez R. Dysregulated molecular pathways in amyotrophic lateral sclerosis&#x2013;frontotemporal dementia spectrum disorder. EMBO J. 2017;36:2931&#x2013;2950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641681</ArticleId><ArticleId IdType="pubmed">28916614</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256. doi: 10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268. doi: 10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, et al. The C9orf72GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. 2013;339:1335&#x2013;1338. doi: 10.1126/science.1232927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1232927</ArticleId><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PEA, et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron. 2013;77:639&#x2013;646. doi: 10.1016/j.neuron.2013.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.02.004</ArticleId><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc. Natl Acad. Sci. USA. 2013;110:E4968&#x2013;E4977. doi: 10.1073/pnas.1315438110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1315438110</ArticleId><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference><Reference><Citation>Saberi S, et al. Sense-encoded poly-GR dipeptide repeat proteins correlate to neurodegeneration and uniquely co-localize with TDP-43 in dendrites of repeat-expanded C9orf72 amyotrophic lateral sclerosis. Acta Neuropathol. 2018;135:459&#x2013;474. doi: 10.1007/s00401-017-1793-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1793-8</ArticleId><ArticleId IdType="pmc">PMC5935138</ArticleId><ArticleId IdType="pubmed">29196813</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakae N, et al. Poly-GR dipeptide repeat polymers correlate with neurodegeneration and clinicopathological subtypes in C9ORF72-related brain disease. Acta Neuropathol. Commun. 2018;6:63. doi: 10.1186/s40478-018-0564-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-018-0564-7</ArticleId><ArticleId IdType="pmc">PMC6054740</ArticleId><ArticleId IdType="pubmed">30029693</ArticleId></ArticleIdList></Reference><Reference><Citation>Quaegebeurn A, et al. Soluble and insoluble dipeptide repeat protein measurements in C9orf72-frontotemporal dementia brains show regional differential solubility and correlation of poly-GR with clinical severity. Acta Neuropathol. Commun. 2020;8:184. doi: 10.1186/s40478-020-01036-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-01036-y</ArticleId><ArticleId IdType="pmc">PMC7650212</ArticleId><ArticleId IdType="pubmed">33168090</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitler AD, Tsuji H. There has been an awakening: emerging mechanisms of C9orf72 mutations in ALS/FTD. Brain Res. 2016;1647:19&#x2013;29. doi: 10.1016/j.brainres.2016.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2016.04.004</ArticleId><ArticleId IdType="pmc">PMC5003651</ArticleId><ArticleId IdType="pubmed">27059391</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz A, et al. Emerging perspectives on dipeptide repeat proteins in C9ORF72 ALS/FTD. Front. Cell Neurosci. 2021;15:637548. doi: 10.3389/fncel.2021.637548.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2021.637548</ArticleId><ArticleId IdType="pmc">PMC7930069</ArticleId><ArticleId IdType="pubmed">33679328</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi S, et al. C9ORF72-ALS/FTD-associated poly(GR) binds ATP5alpha1 and compromises mitochondria function in vivo. Nat. Neurosci. 2019;22:851&#x2013;862. doi: 10.1038/s41593-019-0397-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0397-0</ArticleId><ArticleId IdType="pmc">PMC6800116</ArticleId><ArticleId IdType="pubmed">31086314</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, et al. Quantitative analysis and clinico-pathological correlations of different dipeptide repeat protein pathologies in C9ORF72 mutation carriers. Acta Neuropathol. 2015;130:845&#x2013;861. doi: 10.1007/s00401-015-1476-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1476-2</ArticleId><ArticleId IdType="pubmed">26374446</ArticleId></ArticleIdList></Reference><Reference><Citation>Schludi MH, et al. Distribution of dipeptide repeat proteins in cellular models and C9orf72 mutation cases suggests link to transcriptional silencing. Acta Neuropathol. 2015;130:537&#x2013;555. doi: 10.1007/s00401-015-1450-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1450-z</ArticleId><ArticleId IdType="pmc">PMC4575390</ArticleId><ArticleId IdType="pubmed">26085200</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, et al. C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. Nat. Neurosci. 2016;19:668&#x2013;677. doi: 10.1038/nn.4272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4272</ArticleId><ArticleId IdType="pmc">PMC5138863</ArticleId><ArticleId IdType="pubmed">26998601</ArticleId></ArticleIdList></Reference><Reference><Citation>LaClair KD, et al. Congenic expression of poly-GA but not poly-PR in mice triggers selective neuron loss and interferon responses found in C9orf72 ALS. Acta Neuropathol. 2020;140:121&#x2013;142. doi: 10.1007/s00401-020-02176-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02176-0</ArticleId><ArticleId IdType="pmc">PMC7360660</ArticleId><ArticleId IdType="pubmed">32562018</ArticleId></ArticleIdList></Reference><Reference><Citation>May S, et al. C9orf72 FTLD/ALS-associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestrationC9orf72 FTLD/ALS-associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration. Acta Neuropathol. 2014;128:485&#x2013;503. doi: 10.1007/s00401-014-1329-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1329-4</ArticleId><ArticleId IdType="pmc">PMC4159571</ArticleId><ArticleId IdType="pubmed">25120191</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, et al. Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress. Acta Neuropathol. 2014;128:505&#x2013;524. doi: 10.1007/s00401-014-1336-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1336-5</ArticleId><ArticleId IdType="pmc">PMC4159567</ArticleId><ArticleId IdType="pubmed">25173361</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YB, et al. C9orf72 poly GA RAN-translated protein plays a key role in amyotrophic lateral sclerosis via aggregation and toxicity. Hum. Mol. Genet. 2017;26:4765&#x2013;4777. doi: 10.1093/hmg/ddx350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx350</ArticleId><ArticleId IdType="pmc">PMC5886201</ArticleId><ArticleId IdType="pubmed">28973350</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, et al. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. Sci. Transl. Med. 2017;9:eaai7866. doi: 10.1126/scitranslmed.aai7866.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aai7866</ArticleId><ArticleId IdType="pmc">PMC5576451</ArticleId><ArticleId IdType="pubmed">28356511</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmer C, et al. Poly-GP in cerebrospinal fluid links C9orf72-associated dipeptide repeat expression to the asymptomatic phase of ALS/FTD. EMBO Mol. Med. 2017;9:859&#x2013;868. doi: 10.15252/emmm.201607486.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201607486</ArticleId><ArticleId IdType="pmc">PMC5494528</ArticleId><ArticleId IdType="pubmed">28408402</ArticleId></ArticleIdList></Reference><Reference><Citation>Cammack AJ, et al. Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers. Neurology. 2019;93:e1605&#x2013;e1617. doi: 10.1212/WNL.0000000000008359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008359</ArticleId><ArticleId IdType="pmc">PMC6946465</ArticleId><ArticleId IdType="pubmed">31578300</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett CF, Kordasiewicz HB, Cleveland DW. Antisense drugs make sense for neurological diseases. Annu. Rev. Pharmacol. Toxicol. 2021;61:831&#x2013;852. doi: 10.1146/annurev-pharmtox-010919-023738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pharmtox-010919-023738</ArticleId><ArticleId IdType="pmc">PMC8682074</ArticleId><ArticleId IdType="pubmed">33035446</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran H, et al. Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide. Nat. Med. 2022;28:117&#x2013;124. doi: 10.1038/s41591-021-01557-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01557-6</ArticleId><ArticleId IdType="pmc">PMC8861976</ArticleId><ArticleId IdType="pubmed">34949835</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen L, et al. Antibody therapy targeting RAN proteins rescues C9 ALS/FTD phenotypes in C9orf72 mouse model. Neuron. 2020;105:645&#x2013;662.e11. doi: 10.1016/j.neuron.2019.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.11.007</ArticleId><ArticleId IdType="pmc">PMC7391607</ArticleId><ArticleId IdType="pubmed">31831332</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q, et al. Active poly-GA vaccination prevents microglia activation and motor deficits in a C9orf72 mouse model. EMBO Mol. Med. 2020;12:e10919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7005532</ArticleId><ArticleId IdType="pubmed">31858749</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Gonzalez R, et al. Poly(GR) in C9ORF72-related ALS/FTD compromises mitochondrial function and increases oxidative stress and DNA damage in iPSC-derived motor neurons. Neuron. 2016;92:383&#x2013;391. doi: 10.1016/j.neuron.2016.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.09.015</ArticleId><ArticleId IdType="pmc">PMC5111366</ArticleId><ArticleId IdType="pubmed">27720481</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida S, et al. Production of poly(GA) in C9ORF72 patient motor neurons derived from induced pluripotent stem cells. Acta Neuropathol. 2019;138:1099&#x2013;1101. doi: 10.1007/s00401-019-02083-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02083-z</ArticleId><ArticleId IdType="pmc">PMC6851345</ArticleId><ArticleId IdType="pubmed">31624870</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefura WP, et al. Improved methods for quantifying human chemokine and cytokine biomarker responses: Ultrasensitive ELISA and meso scale electrochemiluminescence assays. Methods Mol. Biol. 2019;2020:91&#x2013;114. doi: 10.1007/978-1-4939-9591-2_7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-9591-2_7</ArticleId><ArticleId IdType="pubmed">31177494</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration. Guidance for industry: Bioanalytical method validation. https://www.regulations.gov/document?D=FDA-2013-D-1020-0002 (2013).</Citation></Reference><Reference><Citation>Andreasson U, et al. A practical guide to immunoassay method validation. Front. Neurol. 2015;19:179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4541289</ArticleId><ArticleId IdType="pubmed">26347708</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeter LHH, et al. Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers. Ann. Clin. Transl. Neurol. 2018;5:583&#x2013;597. doi: 10.1002/acn3.559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.559</ArticleId><ArticleId IdType="pmc">PMC5945959</ArticleId><ArticleId IdType="pubmed">29761121</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, et al. Cerebellar c9RAN proteins associate with clinical and neuropathological characteristics of C9ORF72 repeat expansion carriers. Acta Neuropathol. 2015;130:559&#x2013;573. doi: 10.1007/s00401-015-1474-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1474-4</ArticleId><ArticleId IdType="pmc">PMC4575385</ArticleId><ArticleId IdType="pubmed">26350237</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, et al. Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72. Acta Neuropathol. 2015;130:863&#x2013;876. doi: 10.1007/s00401-015-1480-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1480-6</ArticleId><ArticleId IdType="pmc">PMC4655160</ArticleId><ArticleId IdType="pubmed">26437865</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallabh SM, et al. Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development. Proc. Natl Acad. Sci. USA. 2019;116:7793&#x2013;7798. doi: 10.1073/pnas.1901947116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1901947116</ArticleId><ArticleId IdType="pmc">PMC6475435</ArticleId><ArticleId IdType="pubmed">30936307</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoukry RS, et al. Longitudinal changes in resting state networks in early presymptomatic carriers of C9orf72 expansions. Neuroimage Clin. 2020;28:102354. doi: 10.1016/j.nicl.2020.102354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2020.102354</ArticleId><ArticleId IdType="pmc">PMC7406915</ArticleId><ArticleId IdType="pubmed">32769055</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnan G, et al. CRISPR deletion of the C9ORF72 promoter in ALS/FTD patient motor neurons abolishes production of dipeptide repeat proteins and rescue neurodegeneration. Acta Neuropathol. 2020;140:81&#x2013;84. doi: 10.1007/s00401-020-02154-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02154-6</ArticleId><ArticleId IdType="pmc">PMC7300081</ArticleId><ArticleId IdType="pubmed">32266467</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonobe Y, et al. A C. elegans model of C9orf72-associatred ALS/FTD uncovers a conserved role for eIF2D in RAN translation. Nat. Commun. 2021;12:6025. doi: 10.1038/s41467-021-26303-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26303-x</ArticleId><ArticleId IdType="pmc">PMC8519953</ArticleId><ArticleId IdType="pubmed">34654821</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>